Y Intercept Hong Kong Ltd Makes New $9.91 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Y Intercept Hong Kong Ltd acquired a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 9,425 shares of the biopharmaceutical company's stock, valued at approximately $9,908,000. Regeneron Pharmaceuticals makes up 0.6% of Y Intercept Hong Kong Ltd's investment portfolio, making the stock its 12th biggest position.

Several other large investors also recently modified their holdings of the stock. MML Investors Services LLC boosted its stake in Regeneron Pharmaceuticals by 13.9% in the 3rd quarter. MML Investors Services LLC now owns 5,315 shares of the biopharmaceutical company's stock valued at $5,587,000 after buying an additional 648 shares in the last quarter. World Investment Advisors LLC bought a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at $44,221,000. iSAM Funds UK Ltd acquired a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $472,000. National Bank of Canada FI increased its position in shares of Regeneron Pharmaceuticals by 66.3% during the 3rd quarter. National Bank of Canada FI now owns 71,159 shares of the biopharmaceutical company's stock worth $74,805,000 after purchasing an additional 28,365 shares in the last quarter. Finally, iA Global Asset Management Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.5% during the 3rd quarter. iA Global Asset Management Inc. now owns 13,186 shares of the biopharmaceutical company's stock valued at $13,862,000 after purchasing an additional 200 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Trading Up 1.3 %

REGN traded up $10.00 during midday trading on Monday, reaching $788.00. 1,027,297 shares of the company were exchanged, compared to its average volume of 549,936. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. Regeneron Pharmaceuticals, Inc. has a one year low of $735.95 and a one year high of $1,211.20. The stock has a market capitalization of $86.59 billion, a P/E ratio of 19.50, a PEG ratio of 3.00 and a beta of 0.08. The stock's 50-day simple moving average is $871.59 and its 200 day simple moving average is $1,010.52.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on REGN shares. Leerink Partners reaffirmed a "market perform" rating and set a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, September 24th. JPMorgan Chase & Co. dropped their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an "overweight" rating for the company in a report on Thursday, October 24th. Truist Financial reduced their price objective on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a "buy" rating on the stock in a research note on Friday, November 1st. Leerink Partnrs lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, September 24th. Finally, Barclays lowered their target price on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $1,107.29.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.